Personalized T-Cell therapy takes on pancreatic cancer
Disease control
Not yet recruiting
This early-phase trial tests a new treatment called MT-601 for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. MT-601 uses a patient's own immune cells, specially trained to attack multiple cancer targets, given alongside chemotherapy. The …
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 04:12 UTC